55 results on '"Ullmann, Andrew"'
Search Results
2. Impact of immunosuppressive and antifungal drugs on PBMC- and whole blood-based flow cytometric CD154+Aspergillus fumigatus specific T-cell quantification.
- Author
-
Page, Lukas, Lauruschkat, Chris D., Helm, Johanna, Weis, Philipp, Lazariotou, Maria, Einsele, Hermann, Ullmann, Andrew J., Loeffler, Juergen, and Wurster, Sebastian
- Subjects
IMMUNOSUPPRESSIVE agents ,ASPERGILLUS fumigatus ,VIRAL antigens ,BLOOD cells ,AMPHOTERICIN B ,ANTIFUNGAL agents ,BLOOD group antigens - Abstract
Flow cytometric quantification of CD154
+ mould specific T-cells in antigen-stimulated peripheral blood mononuclear cells (PBMCs) or whole blood has been described as a supportive biomarker to diagnose invasive mould infections and to monitor therapeutic outcomes. As patients at risk frequently receive immunosuppressive and antifungal medication, this study compared the matrix-dependent impact of representative drugs on CD154+ T-cell detection rates. PBMCs and whole blood samples from healthy adults were pre-treated with therapeutic concentrations of liposomal amphotericin B, voriconazole, posaconazole, cyclosporine A (CsA) or prednisolone. Samples were then stimulated with an Aspergillus fumigatus lysate or a viral antigen cocktail (CPI) and assessed for CD154+ T-helper cell frequencies. Specific T-cell detection rates and technical assay properties remained largely unaffected by exposure of both matrices to the studied antifungals. By contrast, CsA and prednisolone pre-treatment of isolated PBMCs and whole blood adversely impacted specific T-cell detection rates and caused elevated inter-replicate variation. Unexpectedly, the whole blood-based protocol that uses additional α-CD49d co-stimulation was less susceptible to CsA and prednisolone despite prolonged drug exposure in the test tube. Accordingly, addition of α-CD49d during PBMC stimulation partially attenuated the impact of immunosuppressive drugs on test performance. Translating these results into the clinical setting, false-negative results of CD154+ antigen-specific T-cell quantification need to be considered in patients receiving T-cell-active immunosuppressive medication. Optimized co-stimulation regimes with α-CD49d could contribute to an improved feasibility of functional T-cell assays in immunocompromised patient populations. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
3. Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
- Author
-
Ruhnke, Markus, Cornely, Oliver A., Schmidt‐Hieber, Martin, Alakel, Nael, Boell, Boris, Buchheidt, Dieter, Christopeit, Maximilian, Hasenkamp, Justin, Heinz, Werner J., Hentrich, Marcus, Karthaus, Meinolf, Koldehoff, Michael, Maschmeyer, Georg, Panse, Jens, Penack, Olaf, Schleicher, Jan, Teschner, Daniel, Ullmann, Andrew John, Vehreschild, Maria, and Lilienfeld‐Toal, Marie
- Subjects
MUCORMYCOSIS ,MYCOSES ,COMMUNICABLE diseases ,CANCER patients ,CANCER-related mortality ,ANTIFUNGAL agents - Abstract
Summary: Background: Invasive fungal diseases remain a major cause of morbidity and mortality in cancer patients undergoing intensive cytotoxic therapy. The choice of the most appropriate antifungal treatment (AFT) depends on the fungal species suspected or identified, the patient's risk factors (eg length and depth of granulocytopenia) and the expected side effects. Objectives: Since the last edition of recommendations for 'Treatment of invasive fungal infections in cancer patients' of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) in 2013, treatment strategies were gradually moving away from solely empirical therapy of presumed or possible invasive fungal diseases (IFDs) towards pre‐emptive therapy of probable IFD. Methods: The guideline was prepared by German clinical experts for infections in cancer patients in a stepwise consensus process. MEDLINE was systematically searched for English‐language publications from January 1975 up to September 2019 using the key terms such as 'invasive fungal infection' and/or 'invasive fungal disease' and at least one of the following: antifungal agents, cancer, haematological malignancy, antifungal therapy, neutropenia, granulocytopenia, mycoses, aspergillosis, candidosis and mucormycosis. Results: AFT of IFDs in cancer patients may include not only antifungal agents but also non‐pharmacologic treatment. In addition, the armamentarium of antifungals for treatment of IFDs has been broadened (eg licensing of isavuconazole). Additional antifungals are currently under investigation or in clinical trials. Conclusions: Here, updated recommendations for the treatment of proven or probable IFDs are given. All recommendations including the levels of evidence are summarised in tables to give the reader rapid access to key information. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie
- Author
-
Laws, Hans-Jürgen, Baumann, Ulrich, Bogdan, Christian, Burchard, Gerd, Christopeit, Maximilian, Hecht, Jane, Heininger, Ulrich, Hilgendorf, Inken, Kern, Winfried, Kling, Kerstin, Kobbe, Guido, Külper, Wiebe, Lehrnbecher, Thomas, Meisel, Roland, Simon, Arne, Ullmann, Andrew, de Wit, Maike, and Zepp, Fred
- Published
- 2020
- Full Text
- View/download PDF
5. Development and evaluation of a whole blood-based approach for flow cytometric quantification of CD154+ mould-reactive T cells.
- Author
-
Weis, Philipp, Helm, Johanna, Page, Lukas, Lauruschkat, Chris D, Lazariotou, Maria, Einsele, Hermann, Loeffler, Juergen, Ullmann, Andrew J, and Wurster, Sebastian
- Abstract
CD154
+ mould-reactive T cells were proposed as a novel biomarker in the diagnosis of invasive mycoses. As PBMC-based protocols for flow cytometric quantification of these cells are logistically challenging and susceptible to preanalytic delays, this study evaluated and optimized a whole blood-based method for the detection of mould-reactive T cells. Blood collection tubes containing costimulatory antibodies and Aspergillus fumigatus mycelial lysates were inoculated with heparinized whole blood from healthy adults, and detection rates of CD154+ /CD4+ A. fumigatus reactive T cells were compared with PBMC-based detection using samples from the same donors. In contrast to the PBMC-based method, double costimulation with αCD28 and αCD49d was crucial for reliable whole blood stimulation. Optimizing stimulation schemes for both matrixes, significantly higher specific T-cell detection rates were achieved by the whole blood-based method, whereas the unspecific background stimulation remained low. MHC II-dependent CD154+ upregulation was demonstrated for both matrixes. Excellent correlation and reproducible conversion factors between whole blood and PBMC-based results were observed. Using frozen ready-to-use test tubes containing costimulatory antibodies and lysates, detection rates of specific T cells were comparable to freshly prepared blood collection tubes. The optimized whole blood-based protocol was also used to detect Rhizopus arrhizus and Rhizomucor pusillus reactive T cells, resulting in 1.5- to 2.7-fold higher detection rates compared with PBMC-based measurement. In summary, the whole blood protocol is a robust, highly sensitive, and cost-effective method for mould-reactive T-cell quantification, allowing for point-of-care sample stimulation and contributing to better assay standardization in multi-centre evaluation of mould reactive T-cell quantification. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
6. Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT.
- Author
-
Schmidt-Hieber, Martin, Engelhard, Dan, Ullmann, Andrew, Ljungman, Per, Maertens, Johan, Martino, Rodrigo, Rovira, Montserrat, Shaw, Peter J., Robin, Christine, Faraci, Maura, Byrne, Jenny, Schäfer-Eckart, Kerstin, Einsele, Hermann, Faber, Edgar, Rigacci, Luigi, Saccardi, Riccardo, Balaguer-Rosello, Aitana, Isaksson, Cecilia, Christopeit, Maximilian, and Tridello, Gloria
- Subjects
HEMATOPOIETIC stem cell transplantation ,PARAINFLUENZA viruses ,CENTRAL nervous system ,COMMUNICABLE diseases ,LEUKOCYTE count ,LONGITUDINAL method ,DRUG-induced abnormalities - Abstract
We performed a prospective study to evaluate the types and characteristics of central nervous system (CNS) disorders in patients after hematopoietic stem cell transplantation. The study included 163 episodes of CNS disorders of which 58 (36%) were infections. Proven or probable infections were documented in 34 patients and included fungi (n = 10, 29%), viruses (n = 12, 35%), Toxoplasma spp. (n = 9, 27%) and bacteria (n = 3, 9%). Non-infectious neurological disorders (n = 105, 64%) frequently encompassed metabolic/drug-induced abnormalities (n = 28, 27%) or cerebral vascular events (n = 22, 21%). Median onset times were later for infectious (day + 101) vs non-infectious neurological disorders (day + 50, p = 0.009). An unremarkable cranial CT scan was found in 33% of infection episodes. Absence of cerebrospinal fluid pleocytosis despite a normal or increased peripheral blood white blood cell count occurred in 26% of infections. Day-30 mortality rates were significantly higher for fungal (87%) vs non-fungal infections (40%, p < 0.001). Significantly higher mortality rates were also documented for cerebral vascular events than for other non-infectious disorders (86% vs 34%, p < 0.001). Our prospective study shows that diagnostic findings in CNS infections might differ between hematopoietic stem cell transplant recipients and immunocompetent hosts. Special awareness and timely initiation of adequate diagnostics are crucial to improve the prognosis of these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO).
- Author
-
Ruhnke, Markus, Behre, Gerhard, Buchheidt, Dieter, Christopeit, Maximilian, Hamprecht, Axel, Heinz, Werner, Heussel, Claus‐Peter, Horger, Marius, Kurzai, Oliver, Karthaus, Meinolf, Löffler, Jürgen, Maschmeyer, Georg, Penack, Olaf, Rieger, Christina, Rickerts, Volker, Ritter, Jörg, Schmidt‐Hieber, Martin, Schuelper, Nikolai, Schwartz, Stefan, and Ullmann, Andrew
- Subjects
CANCER diagnosis ,MYCOSES ,GRANULOCYTOPENIA ,HEMATOLOGY ,ANTIFUNGAL agents - Abstract
Summary: Invasive fungal diseases (IFD) are a primary cause of morbidity and mortality in patients with haematological malignancies. These infections are mostly life‐threatening and an early diagnosis and initiation of appropriate antifungal therapy are essential for the clinical outcome. Most commonly, Aspergillus and Candida species are involved. However, other Non‐Aspergillus moulds are increasingly identified in case of documented IFD. For definite diagnosis of IFD, a combination of diagnostic tools have to be applied, including conventional mycological culture and non‐conventional microbiological tests such as antibody/antigen and molecular tests, as well as histopathology and radiology. Although varying widely in cancer patients, the risk of invasive fungal infection is highest in those with allogeneic stem cell transplantation and those with acute leukaemia and markedly lower in patients with solid cancer. Since the last edition of Diagnosis of Invasive Fungal Diseases recommendations of the German Society for Hematology and Oncology in 2012, integrated care pathways have been proposed for the management and therapy of IFDs with either a diagnostic driven strategy as opposed to a clinical or empirical driven strategy. This update discusses the impact of this additional evidence and effective revisions. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.
- Author
-
Maertens, Johan, Selleslag, Dominik, Heinz, Werner J., Saulay, Mikael, Rahav, Galia, Giladi, Michael, Aoun, Mickael, Kovanda, Laura, Kaufhold, Achim, Engelhardt, Marc, Cornely, Oliver A., Herbrecht, Raoul, and Ullmann, Andrew J.
- Subjects
HEMATOLOGY ,VORICONAZOLE ,ANTIFUNGAL agents ,ASPERGILLOSIS ,IMMUNOCOMPROMISED patients - Abstract
Summary: Treatment outcomes in patients with proven/probable vs possible invasive mould disease (IMD; 2008 European Organisation for Research and Treatment of Cancer/Mycoses Study Group [EORTC/MSG] criteria) needed further assessment. The Phase III SECURE trial compared isavuconazole vs voriconazole for treatment of IMD. This post hoc analysis assessed all‐cause mortality (ACM) through day 42 (primary endpoint) and day 84, overall and clinical success at end of treatment (EOT), and drug‐related treatment‐emergent adverse events (TEAEs) in subgroups with proven/probable or possible IMD. Of 516 randomised patients, 304 (58.9%) had proven/probable IMD and 164 (31.8%) had possible IMD as per EORTC/MSG criteria; 48 did not have IMD. Across treatment groups, day 42 and day 84 ACM were numerically lower for possible vs proven/probable IMD (day 42: 17.1% vs 21.1%; P = 0.3, day 84: 26.2% vs 32.6%; P = 0.15). Overall and clinical success at EOT were significantly higher for possible IMD compared with proven/probable IMD (48.2% vs 36.2%; P = 0.01, 75.0% vs 63.1%; P = 0.01 respectively). Fewer drug‐related TEAEs were reported with isavuconazole compared with voriconazole in patients with either proven/probable or possible IMD. Compared with patients with proven/probable IMD, those with possible IMD demonstrated higher overall and clinical success rates, supporting early initiation of antifungal treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.
- Author
-
Ullmann, Andrew, Schmidt-Hieber, Martin, Bertz, Hartmut, Heinz, Werner, Kiehl, Michael, Krüger, William, Mousset, Sabine, Neuburger, Stefan, Neumann, Silke, Penack, Olaf, Silling, Gerda, Vehreschild, Jörg, Einsele, Hermann, Maschmeyer, Georg, Ullmann, Andrew J, Heinz, Werner J, Krüger, William, Vehreschild, Jörg Janne, and Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation)
- Subjects
HEMATOPOIETIC stem cell transplantation ,COMMUNICABLE disease treatment ,ANTIBIOTIC prophylaxis ,COMPLICATIONS from organ transplantation ,TREATMENT effectiveness ,EVIDENCE-based medicine ,MEDICAL protocols - Abstract
Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT) remain a clinical challenge. This is a guideline provided by the AGIHO (Infectious Diseases Working Group) of the DGHO (German Society for Hematology and Medical Oncology). A core group of experts prepared a preliminary guideline, which was discussed, reviewed, and approved by the entire working group. The guideline provides clinical recommendations for the preventive management including prophylactic treatment of viral, bacterial, parasitic, and fungal diseases. The guideline focuses on antimicrobial agents but includes recommendations on the use of vaccinations. This is the updated version of the AGHIO guideline in the field of allogeneic haematopoietic stem cell transplantation utilizing methods according to evidence-based medicine criteria. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. Erratum zu: Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie
- Author
-
Laws, Hans-Jürgen, Baumann, Ulrich, Bogdan, Christian, Burchard, Gerd, Christopeit, Maximilian, Hecht, Jane, Heininger, Ulrich, Hilgendorf, Inken, Kern, Winfried, Kling, Kerstin, Kobbe, Guido, Külper, Wiebe, Lehrnbecher, Thomas, Meisel, Roland, Simon, Arne, Ullmann, Andrew, de Wit, Maike, and Zepp, Fred
- Abstract
Copyright of Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
11. Susceptibility of A. fumigatus‐specific T‐cell assays to pre‐analytic blood storage and PBMC cryopreservation greatly depends on readout platform and analytes.
- Author
-
Lauruschkat, Chris D., Wurster, Sebastian, Page, Lukas, Lazariotou, Maria, Dragan, Mariola, Weis, Philipp, Ullmann, Andrew J., Einsele, Hermann, and Löffler, Jürgen
- Subjects
T cells ,FLOW cytometry ,ASPERGILLOSIS ,CRYOPRESERVATION of cells ,CYTOKINES - Abstract
Summary: Mould‐specific T cells detectable by flow cytometry or ELISPOT were proposed as a novel biomarker in invasive aspergillosis. To define protocols facilitating sample shipment and longitudinal analysis, this study evaluated the susceptibility of different functional assays for A. fumigatus‐specific T‐cell quantification and characterisation to pre‐analytic delays. PBMCs from 6 healthy donors were analysed after immediate isolation, after 6 hours whole blood storage or after cryopreservation using 3 different common media. Functional responses to A. fumigatus lysate stimulation were comparatively assessed by flow cytometry, ELISPOT and 14‐plex cytokine assay. After 6 hours pre‐analytic storage, all functional assays showed reduced detection rates, higher coefficients of variation (CV) and widely varying individual recovery indices of specific T‐cell response. While cryopreservation resulted in sufficient yields and largely unaltered cellular composition, outcomes of functional readouts significantly differed from freshly processed samples. For CD154‐based flow cytometry, only cryopreservation in RPMI supplemented with autologous serum resulted in satisfactory detection rates and CVs. For ELISPOT and cytokine secretion assays, none of the cryopreservation protocols provided sufficient concordance with immediately processed samples. Even using the same readout platform, individual analytes widely varied in their susceptibility to cryopreservation, highlighting that distinct optimisation is required depending on the downstream assay. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
12. Analysis of the in vitro activity of human neutrophils against Aspergillus fumigatus in presence of antifungal and immunosuppressive agents.
- Author
-
Decker, Christina, Wurster, Sebastian, Lazariotou, Maria, Hellmann, Anna-Maria, Einsele, Hermann, Ullmann, Andrew J, and Löffler, Jürgen
- Abstract
Neutrophils are essential in the first line defense against moulds. This in vitro study assessed different neutrophil effector mechanisms in the presence of clinically relevant antifungal and immunosuppressive agents. Therapeutic concentrations of liposomal amphotericin B led to reduced IL-8 and oxidative burst response to the synthetic stimulus PMA, whereas no major alterations of oxidative burst, phagocytosis, or cytokine response to germinated stages of Aspergillus fumigatus and no supra-additive effects of antifungal and immunosuppressive drugs were observed. Conventional and liposomal amphotericin B as well as voriconazole, however, led to reduced neutrophil extracellular trap formation in response to A. fumigatus germ tubes. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
- Author
-
Mellinghoff, Sibylle C., Panse, Jens, Alakel, Nael, Behre, Gerhard, Buchheidt, Dieter, Christopeit, Maximilian, Hasenkamp, Justin, Kiehl, Michael, Koldehoff, Michael, Krause, Stefan W., Lehners, Nicola, von Lilienfeld-Toal, Marie, Löhnert, Annika Y., Maschmeyer, Georg, Teschner, Daniel, Ullmann, Andrew J., Penack, Olaf, Ruhnke, Markus, Mayer, Karin, and Ostermann, Helmut
- Subjects
HEMATOLOGIC malignancies ,COMMUNICABLE disease treatment ,MYCOSES ,ANTIFUNGAL agents ,IMMUNOCOMPROMISED patients ,AMPHOTERICIN B ,NEUTROPENIA ,ONCOLOGY ,PATIENTS ,PREVENTION ,THERAPEUTICS ,SOCIETIES ,ACUTE myeloid leukemia treatment ,MYELODYSPLASTIC syndromes treatment ,HETEROCYCLIC compounds ,VORICONAZOLE ,CLINICAL trials ,DRUG monitoring ,HEMATOLOGY ,HEMATOPOIETIC stem cell transplantation ,MEDICAL societies ,MYELODYSPLASTIC syndromes ,PREVENTIVE health services ,ACUTE myeloid leukemia - Abstract
Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and recipients of allogeneic haematopoietic stem cell transplants (HSCT). Despite the development of new treatment options in the past decades, IFI remains a concern due to substantial morbidity and mortality in these patient populations. In addition, the increasing use of new immune modulating drugs in cancer therapy has opened an entirely new spectrum of at risk periods. Since the last edition of antifungal prophylaxis recommendations of the German Society for Haematology and Medical Oncology in 2014, seven clinical trials regarding antifungal prophylaxis in patients with haematological malignancies have been published, comprising 1227 patients. This update assesses the impact of this additional evidence and effective revisions. Our key recommendations are the following: prophylaxis should be performed with posaconazole delayed release tablets during remission induction chemotherapy for AML and MDS (AI). Posaconazole iv can be used when the oral route is contraindicated or not feasible. Intravenous liposomal amphotericin B did not significantly decrease IFI rates in acute lymphoblastic leukaemia (ALL) patients during induction chemotherapy, and there is poor evidence to recommend it for prophylaxis in these patients (CI). Despite substantial risk of IFI, we cannot provide a stronger recommendation for these patients. There is poor evidence regarding voriconazole prophylaxis in patients with neutropenia (CII). Therapeutic drug monitoring TDM should be performed within 2 to 5 days of initiating voriconazole prophylaxis and should be repeated in case of suspicious adverse events or of dose changes of interacting drugs (BIItu). General TDM during posaconazole prophylaxis is not recommended (CIItu), but may be helpful in cases of clinical failure such as breakthrough IFI for verification of compliance or absorption. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
- Author
-
Cornely, Oliver A., Robertson, Michael N., Haider, Shariq, Grigg, Andrew, Geddes, Michelle, Aoun, Mickael, Heinz, Werner J., Raad, Issam, Schanz, Urs, Meyer, Ralf G., Hammond, Sarah P., Mullane, Kathleen M., Ostermann, Helmut, Ullmann, Andrew J., Zimmerli, Stefan, Van Iersel, M. L. P. S., Hepler, Deborah A., Waskin, Hetty, Kartsonis, Nicholas A., and Maertens, Johan
- Subjects
PHARMACOKINETICS ,COMMUNICABLE disease treatment ,MYCOSES ,MYELODYSPLASTIC syndromes ,PATIENTS ,PROGNOSIS ,DISEASE risk factors - Abstract
Objectives: A two-part (Phase 1B/3), sequential, open-label, multicentre study evaluated the pharmacokinetics (PK) and safety of intravenous (iv) posaconazole given as antifungal prophylaxis to neutropenic patients with AML or myelodysplastic syndrome (MDS) or to recipients at risk of invasive fungal disease (IFD) after allogeneic HSCT.Methods: Patients (N = 237) received 300 mg of posaconazole iv twice daily on day 1, followed by 300 mg of posaconazole iv once daily for 4-28 days. After at least 5 days, patients were randomly assigned to receive posaconazole oral suspension, 400 mg twice daily or 200 mg three times daily, to complete a 28 day treatment course. Primary PK parameters were steady-state average concentration over the dosing interval (Cavg) and posaconazole trough levels (Cmin).Results: Mean posaconazole Cmin was 1320 ng/mL (day 6) and 1297 ng/mL (day 8); steady-state Cmin was 1090 ng/mL (day 10). Mean steady-state posaconazole Cavg was 1500 ng/mL (day 10 or 14) and was similar in HSCT recipients (1560 ng/mL) and AML/MDS patients (1470 ng/mL). The most commonly reported treatment-related adverse events were diarrhoea (8%), nausea (5%) and rash (5%). IFD was reported in 3/237 patients (1%; 2 proven, 1 probable).Conclusions: Intravenous posaconazole at 300 mg was well tolerated, resulted in adequate steady-state systemic exposure and was associated with a low incidence of IFD in this population at high risk.Trial Registry and Number: ClinicalTrials.gov, NCT01075984. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
15. Mucorales spores induce a proinflammatory cytokine response in human mononuclear phagocytes and harbor no rodlet hydrophobins.
- Author
-
Wurster, Sebastian, Thielen, Vanessa, Weis, Philipp, Walther, Paul, Elias, Johannes, Waaga-Gasser, Ana Maria, Dragan, Mariola, Dandekar, Thomas, Einsele, Hermann, Löffler, Jürgen, and Ullmann, Andrew J.
- Subjects
IMMUNOCOMPROMISED patients ,ASCOMYCETES ,MONOCYTES ,DENDRITIC cells ,CYTOKINES - Abstract
Mucormycoses are life-threatening infections in immunocompromised patients. This study characterizes the response of human mononuclear cells to different Mucorales and Ascomycota. PBMC, monocytes, and monocyte derived dendritic cells (moDCs) from healthy donors were stimulated with resting and germinated stages of Mucorales and Ascomycota. Cytokine response and expression of activation markers were studied. Both inactivated germ tubes and resting spores ofRhizopus arrhizusand other human pathogenic Mucorales species significantly stimulated mRNA synthesis and secretion of proinflammatory cytokines. Moreover,R. arrhizusspores induced the upregulation of co-stimulatory molecules on moDCs and a specific T-helper cell response. Removal of rodlet hydrophobins by hydrofluoric acid treatment ofA. fumigatusconidia resulted in enhanced immunogenicity, whereas the cytokine response of PBMCs to dormantR. arrhizusspores was not influenced by hydrofluoric acid. Scanning electron micrographs of Mucorales spores did not exhibit any morphological correlates of rodlet hydrophobins. Taken together, this study revealed striking differences in the response of human mononuclear cells to resting stages of Ascomycota and Mucorales, which may be explained by absence of an immunoprotective hydrophobin layer in Mucorales spores. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
16. Intra- and inter-individual variability of Aspergillus fumigatus reactive T-cell frequencies in healthy volunteers in dependency of mould exposure in residential and working environment.
- Author
-
Wurster, Sebastian, Weis, Philipp, Page, Lukas, Helm, Johanna, Lazariotou, Maria, Einsele, Hermann, and Ullmann, Andrew J.
- Subjects
ASPERGILLUS fumigatus ,T cells ,FLOW cytometry ,MOLDS (Fungi) ,MYCOSES - Abstract
Invasive aspergillosis remains a deadly disease in immunocompromised patients, whereas the combination of an exaggerated immune response and continuous exposure lead to various hyperinflammatory diseases. This pilot study aimed to gain an overview of the intra- and inter-individual variability in Aspergillus fumigatus reactive T-helper cells in healthy adults and the correlation with environmental mould exposure. In this flow cytometric study, the frequencies of CD154
+ A. fumigatus reactive T cells were evaluated in 70 healthy volunteers. All subjects completed a standardised questionnaire addressing their mould exposure. Subjects with intensive mould exposure in their professional or residential surrounding demonstrated considerably higher mean frequencies of A. fumigatus reactive T-helper and T-memory cells. Comparative evaluation of multiple measurements over time demonstrated relatively conserved reactive T-cell frequencies in the absence of major changes to the exposure profile, whereas those frequently exposed in professional environment or with changes to their risk score demonstrated a marked dependency of antigen reactive T-cell frequencies on recent mould exposure. This pilot study was the first to provide data on the intra-individual variability in A. fumigatus reactive T-cell frequencies and its linkage to mould encounter. Fungus reactive T cells are to be considered a valued tool for the assessment of environmental mould exposure. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
17. The 'Choosing Wisely' initiative in infectious diseases.
- Author
-
Lehmann, Clara, Berner, Reinhard, Bogner, Johannes, Cornely, Oliver, With, Katja, Herold, Susanne, Kern, Winfried, Lemmen, Sebastian, Pletz, Mathias, Ruf, Bernhard, Salzberger, Bernd, Stellbrink, Hans, Suttorp, Norbert, Ullmann, Andrew, Fätkenheuer, Gerd, and Jung, Norma
- Subjects
COMMUNICABLE disease treatment ,ANTIBIOTICS ,BACTERIURIA ,C-reactive protein ,CANDIDA ,HEALTH promotion ,INFLUENZA vaccines ,MEASLES ,RESPIRATORY infections ,STAPHYLOCOCCUS aureus ,DISEASE management ,THERAPEUTICS - Abstract
Objective: 'Choosing Wisely' is a growing international campaign aiming at practice changes to improve patient health and safety by both, conduct of essential and avoidance of unnecessary diagnostic, preventive and therapeutic procedures. The goal is to create an easily recognizable and distributable list ('Choosing Wisely items') that addresses common over- and underuse in the management of infectious diseases. Methods: The German Society of Infectious Diseases (DGI) participates in the campaign 'Klug Entscheiden' by the German Society of Internal Medicine. Committee members of the (DGI) listed potential 'Choosing Wisely items'. Topics were subjected to systematic evidence review and top ten items were selected for appropriateness. Five positive and negative recommendations were approved via individual member vote. Results: The final recommendations are: (1) Imperatively start antimicrobial treatment and remove the focus in Staphylococcus aureus bloodstream infection. (2) Critically ill patients with signs of infection need early appropriate antibiotic therapy. (3) Annual influenza vaccination should be given to individuals with age >60 years, patients with specific co-morbidities and to contact persons who may spread influenza to others. (4) All children should receive measles vaccine. (5) Prefer oral formulations of highly bioavailable antimicrobials whenever possible. (6) Avoid prescribing antibiotics for uncomplicated upper respiratory tract infections. (7) Do not treat asymptomatic bacteriuria with antibiotics. (8) Do not treat Candida detected in respiratory or gastrointestinal tract specimens. (9) Do not prolong prophylactic administration of antibiotics in patients after they have left the operating room. (10) Do not treat an elevated C-reactive protein (CRP) or procalcitonin with antibiotics for patients without signs of infection. Conclusions: Physicians will reduce potential harm to patients and increase the value of health care when implementing these recommendations. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
18. Screening and contact precautions -- A survey on infection control measures for multidrug-resistant bacteria in German university hospitals.
- Author
-
Biehl, Lena M., Bertz, Hartmut, Bogner, Johannes, Dobermann, Ute-Helke, Kessel, Johanna, Krämer, Carolin, Lemmen, Sebastian, von Lilienfeld-Toal, Marie, Peter, Silke, Pletz, Mathias W., Rohde, Holger, Schmiedel, Stefan, Schubert, Sören, Ullmann, Andrew J., Fätkenheuer, Gerd, and Vehreschild, Maria J. G. T.
- Subjects
MULTIDRUG resistance in bacteria ,UNIVERSITY hospitals ,NOSOCOMIAL infection prevention ,HOSPITAL wards ,EVIDENCE-based medicine - Abstract
To assess the scope of infection control measures for multidrug-resistant bacteria in high-risk settings, a survey among university hospitals was conducted. Fourteen professionals from 8 sites participated. Reported policies varied largely with respect to the types of wards conducting screening, sample types used for screening and implementation of contact precautions. This variability among sites highlights the need for an evidence-based consensus of current infection control policies. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
19. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting.
- Author
-
Kaskel, Peter, Tuschy, Silja, Wagner, Alexander, Bannert, Christian, Cornely, Oliver, Glasmacher, Axel, Lipp, Hans-Peter, Ullmann, Andrew, Cornely, Oliver A, and Ullmann, Andrew J
- Subjects
ANTIFUNGAL agents ,AMPHOTERICIN B ,MYCOSES ,HEMATOLOGY ,NEPHROTOXICOLOGY ,CLINICAL trials ,MONTE Carlo method - Abstract
As antifungal agents are frequently used in hematology and oncology, economic data on the empirical therapy of suspected systemic fungal infection are pivotal. Data were analyzed according to: (1) the rate of nephrotoxicity related to treatment with caspofungin in comparison to liposomal amphotericin B (L-AmB) from a randomized clinical trial, (2) the effect of nephrotoxicity on length of hospital stay from a European observational study, and (3) an example of total bottom-up cost in a department of hematology in Germany. All estimates include 95% confidence intervals (CI) using two-stage Monte Carlo simulation on binominal and Gaussian random variables from separate studies with comparable populations. Overall, 8.9 (95% CI 5.9-12.1) fewer patients (of 100 randomized) experienced worsening of renal function with caspofungin vs L-AmB, giving a number needed to treat for one patient to be harmed by L-AmB of 12 (95% CI 8-17). This was estimated to translate into 5.3 extra days in hospital (95% CI 1.6-9.1) per event or 0.48 days (95% CI 0.14-0.88) worth 298 euro (95% CI 89-554) per patient receiving L-AmB rather than caspofungin. From the hospital perspective, use of caspofungin was estimated to be cost-neutral compared to L-AmB at a per diem total hospital cost of 428 euro with, and 1284 euro without, consideration of supplementary reimbursement (Zusatzentgelt) of both L-AmB and caspofungin. The data presented in this scenario show that use of caspofungin in hematology-oncology departments in Germany results in shorter hospital stays and is at least cost-neutral compared to use of L-AmB. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
20. Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole.
- Author
-
Vehreschild, Jörg, Böhme, Angelika, Reichert, Dietmar, Kiehl, Michael, Arenz, Dorothee, Pankraz, Karen, Kochanek, Matthias, Ullmann, Andrew, Cornely, Oliver, Vehreschild, Jörg J, Böhme, Angelika, Kiehl, Michael G, Ullmann, Andrew J, and Cornely, Oliver A
- Subjects
ANTIFUNGAL agents ,COMPARATIVE studies ,HETEROCYCLIC compounds ,INTRAVENOUS therapy ,RESEARCH methodology ,MEDICAL cooperation ,MYCOSES ,ORAL drug administration ,QUESTIONNAIRES ,RESEARCH ,EVALUATION research ,TREATMENT effectiveness ,HEMATOLOGIC malignancies ,VORICONAZOLE ,DISEASE complications - Abstract
Invasive fungal infections are frequent and often deadly complications in patients with malignant hematological diseases. Voriconazole is a third generation triazole antifungal with broad activity against most clinically relevant fungal pathogens. Clinical practice often deviates from insights gained from controlled randomized trials. We conducted a multi-centre survey to evaluate efficacy, safety, treatment indications and dosing of voriconazole outside clinical trials. Patients receiving voriconazole were documented via electronic data capturing. An analysis was conducted after submission of 100 episodes from September 2004 to November 2005. Voriconazole was administered for suspected or proven invasive fungal infection (IFI) (57%), as empirical treatment in patients with fever of unknown origin (21%) and secondary (19%) as well as primary (3%) prophylaxis of IFI. Investigators' assessment of fungal infection often diverted from EORTC/MSG 2002 criteria. A favorable response was reported in 61.4% for suspected or proven IFI and 52.4% for empirical treatment. Mortality was 15%, 26.7% of which was attributable to IFI. Breakthrough fungal infections occurred in four (21.1%) patients with voriconazole as secondary prophylaxis. Toxicity and adverse events comprised elevated liver enzymes and visual disturbances. Although indications frequently deviated from clinical evidence and legal approval, voriconazole showed efficacy and safety, comparable to major controlled clinical trials. Data from this survey demonstrate the difficulty of putting drugs to their approved use in IFI. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
21. Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections.
- Author
-
Heinz, Werner J., Buchheidt, Dieter, and Ullmann, Andrew J.
- Subjects
ASPERGILLOSIS treatment ,LIPOPEPTIDE antibiotics ,SALVAGE therapy ,AMPHOTERICIN B ,ASPERGILLUS - Abstract
In 2001, caspofungin received market authorisation by the FDA and EMA and is globally licensed for several indications, including candidiasis, empirical antifungal therapy in patients with neutropenic fever of unknown origin and treatment of invasive aspergillosis in patients refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B or itraconazole. Despite the lack of phase III data in first-line treatment of invasive aspergillosis, increasing evidence supports the use of first-line therapy. Here, we analyse the evidence of therapeutic activity, represented by favourable response rates, of caspofungin for invasive aspergillosis. A systematic literature search was conducted to identify international presentations and papers reporting monotherapy with caspofungin. Efficacy data are summarised separately for first-line and salvage therapy. Thirty-one papers and published abstracts reported caspofungin therapy for aspergillosis. Fifteen full papers and two abstracts fulfilled the criteria of reporting significant outcome data for caspofungin monotherapy for invasive aspergillosis. Consistent with other analyses and the known safety profile, few adverse events and associated terminations of caspofungin medication have been reported. Although a randomised, comparative, prospective study using caspofungin in this indication is still lacking, growing evidence supports the efficacy of this echinocandin not only for salvage but also for first-line therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
22. EFFICACY AND SAFETY OF CATHETER-DIRECTED THERAPY IN SUBMASSIVE PULMONARY EMBOLISM.
- Author
-
BAJAJ, ARRSH, MCKAY, JENNIFER, BIGDELI, GHAZALEH, KAKKASSERIL, PRATHEEK, ARORA, MONICA, J DELLOSTRITTO, DANIEL, ULLMANN, ANDREW, and J GEMMEL, DAVID
- Subjects
PULMONARY embolism ,SAFETY - Published
- 2022
- Full Text
- View/download PDF
23. Estimated burden of fungal infections in Germany.
- Author
-
Ruhnke, Markus, Groll, Andreas H., Mayser, Peter, Ullmann, Andrew J., Mendling, Werner, Hof, Herbert, and Denning, David W.
- Subjects
MYCOSES ,DISEASE incidence ,EPIDEMIOLOGY ,COHORT analysis ,CLINICAL trials - Abstract
In the late 1980's, the incidence of invasive fungal diseases (IFDs) in Germany was estimated with 36.000 IFDs per year. The current number of fungal infections (FI) occurring each year in Germany is still not known. In the actual analysis, data on incidence of fungal infections in various patients groups at risk for FI were calculated and mostly estimated from various (mostly national) resources. According to the very heterogenous data resources robust data or statistics could not be obtained but preliminary estimations could be made and compared with data from other areas in the world using a deterministic model that has consistently been applied in many countries by the LIFE program ( ). In 2012, of the 80.52 million population (adults 64.47 million; 41.14 million female, 39.38 million male), 20% are children (0-14 years) and 16% of population are ≥65 years old. Using local data and literature estimates of the incidence or prevalence of fungal infections, about 9.6 million (12%) people in Germany suffer from a fungal infection each year. These figures are dominated (95%) by fungal skin disease and recurrent vulvo-vaginal candidosis. In general, considerable uncertainty surrounds the total numbers because IFDs do not belong to the list of reportable infectious diseases in Germany and most patients were not hospitalised because of the IFD but a distinct underlying disease. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
24. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.
- Author
-
Tacke, Daniela, Buchheidt, Dieter, Karthaus, Meinolf, Krause, Stefan, Maschmeyer, Georg, Neumann, Silke, Ostermann, Helmut, Penack, Olaf, Rieger, Christina, Ruhnke, Markus, Sandherr, Michael, Schweer, Katharina, Ullmann, Andrew, and Cornely, Oliver
- Subjects
MYCOSES ,STEM cell transplantation ,INFECTION treatment ,CANCER chemotherapy ,MYELOID leukemia ,NEUTROPENIA ,PATIENTS - Abstract
Invasive fungal infections cause substantial morbidity and mortality in immunocompromised patients, particularly in those with haematological malignancies and recipients of allogeneic haematopoietic stem cell transplantation. Difficulties in diagnosing invasive fungal infections and subsequent delays in treatment initiation lead to unfavourable outcomes and emphasise the importance of prophylaxis. Since the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology in 2009, results of 14 additional clinical studies have been published comprising 2,899 patients and initiating this update. Key recommendations for adult patients are as follows: Posaconazole remains the drug of choice during remission-induction chemotherapy in acute myeloid leukaemia, myelodysplastic syndrome and allogeneic haematopoietic stem cell transplantation with graft versus host disease (AI). In the pre-engraftment period of allogeneic transplantation, several antifungals are appropriate and can be recommended with equal strength: voriconazole (BI), micafungin (BI), fluconazole (BI) and posaconazole (BII). There is poor evidence regarding antifungal prophylaxis in the post-engraftment period of allogeneic haematopoietic stem cell transplantation if no steroids for treatment of graft versus host disease are required. Aerosolised liposomal amphotericin B inhalation in conjunction with fluconazole can be used in patients with prolonged neutropenia (BII). [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
25. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non- albicans Candida species.
- Author
-
Cornely, Oliver A., Vazquez, Jose, Waele, Jan, Betts, Robert, Rotstein, Coleman, Nucci, Marcio, Pappas, Peter G., and Ullmann, Andrew J.
- Subjects
CANDIDIASIS ,CANDIDA albicans ,DRUG efficacy ,AMPHOTERICIN B ,ANTIFUNGAL agents - Abstract
The incidence of invasive candidiasis caused by non- albicans Candida ( NAC) spp. is increasing. The aim of this analysis was to evaluate the efficacy of micafungin, caspofungin and liposomal amphotericin B in patients with invasive candidiasis and candidaemia caused by different Candida spp. This post hoc analysis used data obtained from two randomised phase III trials was conducted to evaluate the efficacy and safety of micafungin vs. caspofungin and micafungin vs. liposomal amphotericin B. Treatment success, clinical response, mycological response and mortality were evaluated in patients infected with C. albicans and NAC spp. Treatment success rates in patients with either C. albicans or NAC infections were similar. Outcomes were similar for micafungin, caspofungin and liposomal amphotericin B. Candida albicans was the most prevalent pathogen recovered (41.0%), followed by C. tropicalis (17.9%) , C. parapsilosis (14.4%), C. glabrata (10.4%), multiple Candida spp. (7.3%) and C. krusei (3.2%). Age, primary diagnosis (i.e. candidaemia or invasive candidiasis), previous corticosteroid therapy and Acute Physiology and Chronic Health Evaluation II score were identified as potential predictors of treatment success and mortality. Micafungin, caspofungin and liposomal amphotericin B exhibit favourable treatment response rates that are comparable for patients infected with different Candida spp. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
26. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
- Author
-
Mousset, Sabine, Buchheidt, Dieter, Heinz, Werner, Ruhnke, Markus, Cornely, Oliver, Egerer, Gerlinde, Krüger, William, Link, Hartmut, Neumann, Silke, Ostermann, Helmut, Panse, Jens, Penack, Olaf, Rieger, Christina, Schmidt-Hieber, Martin, Silling, Gerda, Südhoff, Thomas, Ullmann, Andrew, Wolf, Hans-Heinrich, Maschmeyer, Georg, and Böhme, Angelika
- Subjects
COMMUNICABLE disease treatment ,MYCOSES ,CANCER patients ,ANTIFUNGAL agents ,NEUTROPENIA ,HEMATOLOGY ,DISEASE risk factors - Abstract
The Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) here presents its updated recommendations for the treatment of documented fungal infections. Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. In recent years, new antifungal agents have been licensed, and agents already approved have been studied in new indications. The choice of the most appropriate antifungal treatment depends on the fungal species suspected or identified, the patient's risk factors (e.g., length and depth of neutropenia), and the expected side effects. This guideline reviews the clinical studies that served as a basis for the following recommendations. All recommendations including the levels of evidence are summarized in tables to give the reader rapid access to the information. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
27. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
- Author
-
Weissinger, Florian, Auner, Holger, Bertz, Hartmut, Buchheidt, Dieter, Cornely, Oliver, Egerer, Gerlinde, Heinz, Werner, Karthaus, Meinolf, Kiehl, Michael, Krüger, William, Penack, Olaf, Reuter, Stefan, Ruhnke, Markus, Sandherr, Michael, Salwender, Hans-Jürgen, Ullmann, Andrew, Waldschmidt, Dirk, and Wolf, Hans
- Subjects
ANTI-infective agents ,DENTAL prophylaxis ,FEBRILE seizures ,DRUG therapy ,HEMATOPOIETIC stem cell transplantation ,ONCOLOGY ,HEMATOLOGY - Abstract
More than 18,000 autolgous transplantation were performed in Europe in the year 2009. It as a routine procedure in experienced centres. Even if there is a low mortality rate, infections are a major issue after transplantation, occurring in more than 60 % of the patients. In this review we discuss all aspects of infections after autologous stem transplantation, including epidemiology, diagnostics, therapeutic algorithms, prophylaxis and supportive therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
28. Safety of micafungin in prospective and retrospective clinical trials.
- Author
-
Ullmann, Andrew J. and Klaas, Wibke
- Subjects
MYCOSES ,ANTIFUNGAL agents ,PUBLICATIONS ,AMPHOTERICIN B ,CLINICAL medicine - Abstract
Summary Managing fungal diseases remains a major challenge for clinicians despite the improved armamentarium of antifungal agents. This review identified 19 publications reporting safety data on micafungin. Two of these publications were spin off publications, the remaining 17 (15 prospective, two retrospective) were included in the main assessment. Major adverse events reported which occurred in more than 2% in the study populations were infusion-related, gastro-intestinal and hepatic (LFT parameters elevations). Micafungin demonstrated significantly less renal events compared with liposomal amphotericin B and less hepatic events compared with voriconazole. Compared with fluconazole no significant treatment-related adverse events were found except one trial reporting significantly less somnolence but more chills. Micafungin has a similar favourable safety profile in comparison with other echinocandins or fluconazole. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
29. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.
- Author
-
Cornely, Oliver A., Marty, Francisco M., Stucker, Flavie, Pappas, Peter G., and Ullmann, Andrew J.
- Subjects
DRUG efficacy ,CANCER patients ,CANCER treatment ,CANDIDIASIS ,CLINICAL trials ,PATIENTS - Abstract
Summary The aim of this study was to evaluate micafungin efficacy for treatment of invasive candidiasis/candidaemia in patients with cancer. Modified intent-to-treat populations were analysed from two trials: one, in adults and children with confirmed Candida infection, compared micafungin (adults 100 mg day
−1 ; children 2 mg kg−1 day−1 ) with liposomal amphotericin B (L-AmB 3 mg kg−1 day−1 ); and the other, in adults only, compared micafungin (100 or 150 mg day−1 ) with caspofungin (50 mg day−1 ; 70 mg loading dose). Primary efficacy endpoint in both trials was treatment success, defined as both clinical and mycological response at end of therapy. In the micafungin/L-AmB trial, 183/489 patients had malignancy (37% neutropenic). In the micafungin/caspofungin trial, 176/572 patients had malignancy (26% neutropenic). Micafungin treatment success rates were generally similar in patients with/without malignancy and to rates observed with L-AmB and caspofungin. Most patients with malignancy and neutropenia were successfully treated by all three drugs. For all drugs, incidence of discontinuations because of treatment-related adverse events was similar for patients with malignancy (≤7.7%) vs. no malignancy (≤8.0%). These results suggest that compared with L-AmB and caspofungin, micafungin was effective and well tolerated in patients with candidiasis/candidaemia with/without malignancy. Further prospective trials are recommended to evaluate comparative outcomes with a primary focus on patients with malignancies and invasive candidiasis. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
30. Randomized Study of Early versus Late Immunization with Pneumococcal Conjugate Vaccine after Allogeneic Stem Cell Transplantation.
- Author
-
Cordonnier, Catherine, Labopin, Myriam, Chesnel, Virginie, Ribaud, Patricia, De La Camara, Rafael, Martino, Rodrigo, Ullmann, Andrew J., Parkkali, Terttu, Locasciulli, Anna, Yakouben, Karima, Pauksens, Karlis, Einsele, Hermann, Niederwieser, Dietger, Apperley, Jane, and Ljungman, Per
- Subjects
PNEUMOCOCCAL vaccines ,BACTERIAL vaccines ,VACCINATION ,VACCINES ,IMMUNIZATION ,STEM cell transplantation ,POLYSACCHARIDES ,STREPTOCOCCUS pneumoniae ,MEDICAL research - Abstract
Background. Invasive pneumococcal disease is a life-threatening complication after allogeneic stem cell transplantation, and at least 20% of cases occur within 1 year after transplantation. The 23-valent pneumococcal polysaccharide vaccine (PPV23) has limited efficacy, especially during the first year after transplantation. The immune response to the conjugated vaccines is expected to be better than that to the polysaccharide vaccine, but the optimal timing of vaccination is not defined. Our objective was to show that a 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) was not inferior when first given 3 months after transplantation, compared with when first given 9 months after transplantation. Methods. We performed a multicenter, randomized, noninferiority study involving 158 patients from 13 European Group for Blood and Marrow Transplantation centers who were randomly allocated at ∼100 days after myeloablative stem cell transplantation to receive a series of vaccinations (3 doses of PCV7 given 1 month apart) that was started immediately (i.e., 3 months after transplantation) or 6 months later (i.e., 9 months after transplantation). The primary evaluation criterion was the rate of response (antibody level, ⩾0.15 mg/μL for each of the 7 serotypes) at 1 month after the third dose of PCV7. The noninferiority margin was 20%. All patients were followed up for 24 months after transplantation or until death, whichever occurred first. Results. We found that the response rate was not lower after early vaccination (79% [45 of 57 patients]) than after late vaccination (82% [47 of 57 patients]) (difference, -3.5%; 90% confidence interval, -15.6 to 8.6; not significant). Conclusions. We conclude that PCV7 vaccination at 3 months after stem cell transplantation is not inferior to PCV7 vaccination at 9 months after transplantation. Because invasive pneumococcal disease can occur early, we recommend starting the PCV7 vaccination series at 3 months after transplantation to ensure earlier protection against Streptococcus pneumoniae. However, the early vaccination may result in only short-lasting response and may not prime for a 23-valent pneumococcal polysaccharide vaccine boost as efficiently as the late vaccination. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
31. Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
- Author
-
Böhme, Angelika, Ruhnke, Markus, Buchheidt, Dieter, Cornely, Oliver, Einsele, Herrmann, Enzensberger, Ruxandra, Hebart, Holger, Heinz, Werner, Junghanss, Christian, Karthaus, Meinolf, Krüger, William, Krug, Utz, Kubin, Thomas, Penack, Olaf, Reichert, Dietmar, Reuter, Stefan, Silling, Gerda, Südhoff, Thomas, Ullmann, Andrew, and Maschmeyer, Georg
- Subjects
MYCOSES ,ANTIFUNGAL agents ,CANCER patients ,MORTALITY ,AMPHOTERICIN B ,ASPERGILLOSIS - Abstract
Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. Early antifungal treatment is mandatory to improve survival. Today, a number of effective and better-tolerated but more expensive antifungal agents compared to the former gold standard amphotericin B deoxycholate are available. Clinical decision-making must consider results from numerous studies and published guidelines, as well as licensing status and cost pressure. New developments in antifungal prophylaxis improving survival rates result in a continuous need for actualization. The treatment options for invasive Candida infections include fluconazole, voriconazole, and amphotericin B and its lipid formulations, as well as echinocandins. Voriconazole, amphotericin B, amphotericin B lipid formulations, caspofungin, itraconazole, and posaconazole are available for the treatment of invasive aspergillosis. Additional procedures, such as surgical interventions, immunoregulatory therapy, and granulocyte transfusions, have to be considered. The Infectious Diseases Working Party of the German Society of Hematology and Oncology here presents its 2008 recommendations discussing the dos and do-nots, as well as the problems and possible solutions, of evidence criteria selection. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
32. Nephrotoxicity in the setting of invasive fungal diseases.
- Author
-
Ullmann, Andrew J.
- Subjects
RESEARCH ,DRUG efficacy ,AMPHOTERICIN B ,NEPHROTOXICOLOGY ,COMMUNICABLE disease treatment ,MYCOSES ,THERAPEUTICS - Abstract
Amphotericin B, a broad spectrum antifungal agent, is widely used despite significant adverse events including nephrotoxicity. Nephrotoxicity occurs frequently in patients receiving amphotericin B. Different definitions for nephrotoxicity are reviewed in the context of outcome in patients with invasive fungal diseases. In most publications, mortality was higher in patients experiencing nephrotoxicity and mean hospital length of stay was prolonged. As a consequence, the use of less nephrotoxic antifungal agents could improve treatment outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
33. Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease.
- Author
-
Krishna, Gopal, Martinho, Monika, Chandrasekar, Pranatharthi, Ullmann, Andrew J., and Patino, Hernando
- Subjects
PHARMACOKINETICS ,AZOLES ,STEM cell transplantation ,GRAFT versus host disease ,COMMUNICABLE disease treatment ,MYCOSES ,CLINICAL trials - Abstract
Study Objective. To analyze the pharmacokinetics of posaconazole administered as prophylaxis for invasive fungal infections in recipients of hematopoietic stem cell transplants (HSCTs) who have graft-versus-host disease (GVHD). Design. Pharmacokinetic analysis in a subset of posaconazole-treated patients from a large, multicenter, phase III, randomized, double-blind, double-dummy, parallel-group trial that compared posaconazole with fluconazole. Setting. Ninety international medical centers. Patients. The subset of patients comprised 246 HSCT recipients for whom pharmacokinetic data were available. Intervention. All patients received posaconazole 200 mg oral suspension 3 times/day for a maximum of 16 weeks. Measurements and Main Results. Blood samples were collected after dosing on day 2; at weeks 2, 4, 8, and 12; and on the last day of. oral treatment. After patients had received posaconazole for at least 7 days (i.e., after achieving steady state), both maximum observed posaconazole concentration (Cmax) and average posaconazole concentration (Cav) were determined. Five patients developed invasive fungal infections while receiving treatment. Median Cav and Cmax were 611 and 635 ng/ml, respectively, in these five patients and were 922 and 1360 ng/ml, respectively, in the 241 patients without invasive fungal infection. In patients without invasive fungal infection, posaconazole concentrations were not clinically affected by race, body weight, or age. Median plasma posaconazole concentrations were higher in patients with chronic GVHD than in those with acute GVHD. In 18 patients without invasive fungal infection who experienced diarrhea on the day of sampling, posaconazole concentrations were lower than the concentrations in patients without diarrhea. No relationship was observed between alanine aminotransferase, aspartate aminotransferase, or bilirubin levels and posaconazole concentrations. Conclusion. Posaconazole 200 mg 3 times/day resulted in median plasma drug concentrations sufficiently high to prevent invasive fungal infections in HSCT recipients with GVHD, without compromising patient safety. Plasma posaconazole concentrations are generally unaffected by demographic variables, including race, sex, body weight, and age. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
34. Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High—Loading Dose Regimen with Standard Dosing (AmBiLoad Trial).
- Author
-
Cornely, Oliver A., Maertens, Johan, Bresnik, Mark, Ebrahimi, Ramin, Ullmann, Andrew J., Bouza, Emilio, Heussel, Claus Peter, Lortholary, Olivier, Rieger, Christina, Boehme, Angelika, Aoun, Mickael, Horst, Heinz-August, Thiebaut, Anne, Ruhnke, Markus, Reichert, Dietmar, Vianelli, Nicola, Krause, Stefan W., Olavarria, Eduardo, and Herbrecht, Raoul
- Subjects
AMPHOTERICIN B ,CLINICAL trials ,DRUG interactions ,DRUG side effects ,PATIENTS ,NEPHROTOXICOLOGY ,ASPERGILLOSIS - Abstract
Background. Treatment of invasive mold infection in immunocompromised patients remains challenging. Voriconazole has been shown to have efficacy and survival benefits over amphotericin B deoxycholate, but its utility is limited by drug interactions. Liposomal amphotericin B achieves maximum plasma levels at a dosage of 10 mg/kg per day, but clinical efficacy data for higher doses are lacking. Methods. In a double-blind trial, patients with proven or probable invasive mold infection were randomized to receive liposomal amphotericin B at either 3 or 10 mg/kg per day for 14 days, followed by 3 mg/kg per day. The primary end point was favorable (i.e., complete or partial) response at the end of study drug treatment. Survival and safety outcomes were also evaluated. Results. Of 201 patients with confirmed invasive mold infection, 107 received the 3-mg/kg daily dose, and 94 received the 10-mg/kg daily dose. Invasive aspergillosis accounted for 97% of cases. Hematological malignancies were present in 93% of patients, and 73% of patients were neutropenic at baseline. A favorable response was achieved in 50% and 46% of patients in the 3- and 10-mg/kg groups, respectively (difference, 4%; 95% confidence interval, -10% to 18%; P>); the respective survival rates at 12 weeks were 72% and 59% (difference, 13%; 95% confidence interval, -0.2% to 26%; P>.05). Significantly higher rates of nephrotoxicity and hypokalemia were seen in the high-dose group. Conclusions. In highly immunocompromised patients, the effectiveness of 3 mg/kg of liposomal amphotericin B per day as first-line therapy for invasive aspergillosis is demonstrated, with a response rate of 50% and a 12-week survival rate of 72%. The regimen of 10 mg/kg per day demonstrated no additional benefit and higher rates of nephrotoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
35. Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries.
- Author
-
Ullmann, Andrew J., Sanz, Miguel A., Tramarin, Andrea, Barnes, Rosemary A., Wu, Wenchen, Gerlach, Barbara A., Krobot, Karl J., and Gerth, William C.
- Subjects
AMPHOTERICIN B ,MEDICAL prescriptions ,ANTIFUNGAL agents ,ANTI-infective agents ,INTERNAL medicine ,IONOPHORES ,POLYENE antibiotics ,LENGTH of stay in hospitals - Abstract
Background. Amphotericin B is a widely used broad-spectrum antifungal agent, despite being associated with significant adverse events, including nephrotoxicity. Methods. The present prospective study collected data on outcomes for 418 adult patients treated consecutively with polyenes in hematology and oncology wards in 20 hospitals in Europe. Results. Patients initially received amphotericin B deoxycholate (62% of patients), liposomal amphotericin B (27%), or other lipid formulations of amphotericin B (11%). Of the patients initially treated with amphotericin B deoxycholate, 36% had therapy switched to lipid formulations of amphotericin B, primarily because of increased serum creatinine levels (in 45.7% of patients) or other amphotericin B-attributable adverse events (in 41.3% of patients). Nephrotoxicity, which was defined as a ⩾50% increase in the serum creatinine level, developed in 57% of patients with normal kidney function at baseline. Predictors of nephrotoxicity included formulation type and duration of treatment. Compared with patients without nephrotoxicity, patients with nephrotoxicity had a higher mortality rate (24%), and their mean length of stay in the hospital was prolonged by 8.6 days. Slight increases in the serum creatinine level (i.e., ⩾50%) were associated with a significantly longer stay in the hospital. Severe nephrotoxicity (i.e., a ⩾200% increase in the serum creatinine level) was a significant predictor of death, as were severe underlying medical conditions and documented fungal infection. Conclusion. This prospective study confirmed that, in European hospitals, amphotericin B formulations have a major influence on the length of stay in the hospital and nephrotoxicity-associated mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2006
36. Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections.
- Author
-
Raad, Issam I., Graybill, John R., Bustamante, Ana Beatriz, Cornely, Oliver A., Gaona-Flores, Veronica, Afif, Claude, Graham, Donald R., Greenberg, Richard N., Hadley, Susan, Langston, Amelia, Negroni, Ricardo, Perfect, John R., Pitisuttithum, Punnee, Restrepo, Angela, Schiller, Gary, Pedicone, Lisa, and Ullmann, Andrew J.
- Subjects
MYCOSES ,IMMUNOSUPPRESSION ,CRITICALLY ill ,HOSPITAL patients ,ANTIFUNGAL agents ,TRIAZOLES - Abstract
Background. Invasive fungal infections are found most frequently in immunosuppressed and critically ill hospitalized patients. Antifungal therapy is often required for long periods. Safety data from the clinical development program of the triazole antifungal agent, posaconazole, were analyzed. Methods. A total of 428 patients with refractory invasive fungal infections (n = 362) or febrile neutropenia (n = 66) received posaconazole in 2 phase II/III open-label clinical trials. Also, 109 of these patients received posaconazole therapy for ⩾6 months. Incidences of treatment-emergent, treatment-related, and serious adverse events and abnormal laboratory parameters were recorded during these studies. Results. Treatment-emergent, treatment-related adverse events were reported in 38% of the overall patient population. The most common treatment-related adverse events were nausea (8%) and vomiting (6%). Treatmentrelated serious adverse events occurred in 8% of patients. Low rates of treatment-related corrected QT interval and/or QT interval prolongation (1%) and elevation of hepatic enzymes (2%) were reported as adverse events. Treatment-emergent, treatment-related adverse events occurred at similar rates in patients who received posaconazole therapy for <6 months and ⩾6 months. Conclusions. Prolonged posaconazole treatment was associated with a generally favorable safety profile in seriously ill patients with refractory invasive fungal infections. Long-term therapy did not increase the risk of any individual adverse event, and no unique adverse event was observed with longer exposure to posaconazole. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
37. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and =106/kg T cells may have an adverse effect on transplant-related mortality.
- Author
-
Hartwig, Udo F., Winkelmann, Nils, Wehler, Thomas, Kreiter, Sebastian, Schneider, Peter M., Meyer, Ralf G., Ullmann, Andrew J., Huber, Christoph, Kolbe, Karin, and Herr, Wolfgang
- Subjects
HOMOGRAFTS ,CELL transplantation ,STEM cells ,T cells ,IMMUNITY ,CD antigens ,GLOBULINS - Abstract
In patients undergoing allogeneic peripheral blood stem cell (PBSC) transplantation after reduced-intensity conditioning (RIC), graft-versus-host disease (GVHD) represents a major cause of morbidity and mortality. T-cell depletion (TCD) prevents GVHD but carries potential risks of graft failure, opportunistic infections, and disease relapse. We explored ex vivo TCD of stem cell allografts that were administered after RIC treatment. Thirteen high-risk patients with hematological malignancies were treated with a fludarabine/melphalan-based RIC regimen followed by transplantation of immunomagnetically selected CD34
+ PBSC from HLA-identical sibling or matched unrelated donors. Patients were sequentially enrolled in two cohorts: group A (n=6) received antithymocyte globulin (ATG) during conditioning and 105 donor T cells/kg at transplantation, while group B (n=7) received 106 donor T cells/kg without ATG pretreatment. Primary graft failure occurred in two patients of group A and in one patient of group B. Complete donor chimerism persisting more than 1 year was achieved in two cases per cohort. Acute grade II to IV or chronic extensive GVHD were observed in a total of six patients (group A, 2; group B, 4). Procedure-related deaths were mainly due to severe pneumonia occurring in two patients of group A and in five patients of group B. These results suggest that CD34 selection of reduced-intensity PBSC allografts may cause adverse effects upon specific antimicrobial immunity which can lead to fatal infections, particularly in high-risk patients. In our study, simultaneous add-back of =106 /kg donor T cells was unable to compensate for this deficiency. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
38. Early Detection of Toxoplasma Infection by Molecular Monitoring of Toxoplasma gondii in Peripheral Blood Samples after Allogeneic Stem Cell Transplantation.
- Author
-
Martino, Rodrigo, Bretagne, Stéphane, Einsele, Hermann, Maertens, Johan, Ullmann, Andrew J., Parody, Rocío, Schumacher, Ulrike, Pautas, Cécile, Theunissen, Koen, Schindel, Christine, Muñoz, Carmen, Margall, Nuria, and Cordonnier, Catherine
- Subjects
TOXOPLASMA gondii ,BLOOD testing ,STEM cells ,CELL transplantation ,DNA polymerases ,HEMATOPOIETIC stem cells - Abstract
Background. isolated case reports have shown that recipients of allogeneic hematopoietic stem cell transplants (HSCTs) who develop toxoplasmosis may have circulating Toxoplasma gondii DNA in peripheral blood before the onset of clinical symptoms. Methods. We prospectively studied 106 T gondii-seropositive adult recipients of HSCTs for the incidence of reactivation of toxoplasmosis in the first 6 months after transplantation. Toxoplasmosis infection (TI) was defined by a positive result of polymerase chain reaction (PCR) of peripheral blood specimens, whereas toxoplasmosis disease (TD) was defined as an invasive infection. Results. The incidence of Ti was 16% (95% confidence interval [Cl], 8%-21%), whereas the incidence of TD was 6% (95% Cl, 1%-10%). in the 16 patients with TI, the incidence of disease was 38%, whereas it was 0% in patients without Ti (P .0001). in most patients, the onset of TD or treatment for Ti was preceded by an increase in the parasite load in peripheral blood samples, as determined by quantitative PCR. Conclusions. Toxoplasmosis occurs more commonly after HSCT than has previously been suggested, and routine PCR testing of peripheral blood specimens may be an appropriate tool for guiding preemptive therapy in patients at very high risk of developing invasive disease. [ABSTRACT FROM AUTHOR]
- Published
- 2005
39. Impfungen bei immunsupprimierten Erwachsenen mit hämato-onkologischer Erkrankung.
- Author
-
Ullmann, Andrew J., Karthaus, Meinoif, and Comely, Oliver A.
- Subjects
VACCINATION ,INFLUENZA ,TETANUS ,IMMUNOTHERAPY ,VACCINES ,IMMUNIZATION - Abstract
Copyright of Wiener Medizinische Wochenschrift is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2004
40. Opportunistische Infektionen nach Therapie mit monoklonalen Antikörpern.
- Author
-
Comely, Oliver A., Ullmann, Andrew J., and Karthaus, Meinolf
- Subjects
OPPORTUNISTIC infections ,MONOCLONAL antibodies ,IMMUNOGLOBULINS ,IMMUNOSUPPRESSIVE agents ,PNEUMOCYSTIS pneumonia ,THERAPEUTICS - Abstract
Copyright of Wiener Medizinische Wochenschrift is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2004
41. Aktuelle Entwicklungen in der Diagnostik und Therapie von systemischen Pilzinfektionen bei Krebspatienten.
- Author
-
Karthaus, Meinolf, Ullmann, Andrew J., and Comely, Oliver A.
- Subjects
CANCER patients ,MYCOSES ,INFECTION ,DRUG therapy ,PUBLIC health ,THERAPEUTICS - Abstract
Copyright of Wiener Medizinische Wochenschrift is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2004
42. Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.
- Author
-
Cornely, Oliver A, Wicke, Thomas, Seifert, Harald, Bethe, Ullrich, Schwonzen, Martin, Reichert, Dietmar, Ullmann, Andrew J, Karthaus, Meinolf, Breuer, Kai, Salzberger, Bernd, Diehl, Volker, and Fätkenheuer, Gerd
- Abstract
A prospective, randomized, controlled multicenter trial was performed to evaluate the efficacy and safety of once-daily oral monotherapy with 500 mg levofloxacin in comparison with 4.5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia. Low risk was defined by oral temperature > or = 38.5 degrees C on one occasion or > or = 38.0 degrees C twice within 24 hours and granulocytopenia < or = 500/microL for less than 10 days. The primary end point was defined as defervescence after 72 hours followed by at least 7 afebrile days. Secondary end points were overall response, time to defervescence, survival on day 30, and toxicity. Thirty-four episodes were included. Fever of unknown origin accounted for 26 (76.5%) of the episodes, microbiologically defined infection for 5 (14.7%) of the episodes, and clinically defined infection for 3 (8.8%) of the episodes. On an intent-to-treat basis, all episodes were evaluable for the primary end point. Levofloxacin and piperacillin/tazobactam were successful after 72 hours of treatment in 76.5% and 88.3% of the episodes. Overall response was achieved in 94.1% and 100% of the episodes, respectively. One inpatient in the oral treatment group died of septic shock without identification of a causative pathogen. A larger phase III trial is warranted to further evaluate the lack of inferiority of the oral monotherapy regimen versus standard intravenous therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
43. Treatment of fungal infections in hematology and oncology: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
- Author
-
Böhme, Angelika, Ruhnke, Markus, Buchheidt, Dieter, Karthaus, Meinolf, Einsele, Hermann, Guth, Stefan, Heussel, Gudrun, Heussel, Claus-Peter, Junghanss, Christian, Kern, Winfried K., Kubin, Thomas, Maschmeyer, Georg, Sezer, Orhan, Silling, Gerda, Südhoff, Thomas, Szelényi†, Hubert, and Ullmann, Andrew J.
- Subjects
MYCOSES ,CANCER ,ANTIFUNGAL agents ,NEUTROPENIA - Abstract
The Infectious Diseases Working Party of the German Society of Haematology and Oncology presents their guidelines for the treatment of fungal infections in patients with hematological and oncological malignancies. These guidelines are evidence-based, considering study results, case reports and expert opinions, using the evidence criteria of the Infectious Diseases Society of America (IDSA). The recommendations for major fungal complications in this setting are summarized here. The primary choice of therapy for chronic candidiasis should be fluconazole, reserving caspofungin or amphotericin B (AmB) for use in case of progression of the Candida infection. Patients with candidemia (except C. krusei or C. glabrata) who are in a clinically stable condition without previous azole prophylaxis should receive fluconazole, otherwise AmB or caspofungin. Voriconazole is recommended for the first-line treatment of invasive aspergillosis. The benefit of a combination of AmB and 5-flucytosine has not been demonstrated except in patients with cryptococcal meningitis. Mucormycosis is relatively rare. The drug therapy of choice consists of AmB, desoxycholate or liposomal formulation, in the highest tolerable dosage. Additional surgical intervention has been shown to achieve a lower fatality rate than with antifungal therapy alone. The role of interventional strategies, cytokines/G-CSF, and granulocyte transfusions in invasive fungal infections are further reviewed. These guidelines offer actual standards and discussions on the treatment of oropharyngeal and esophageal candidiasis, invasive candidiasis, cryptococcosis and mould infections. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
44. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
- Author
-
Cornely, Oliver A., Böhme, Angelika, Buchheidt, Dieter, Glasmacher, Axel, Kahl, Christoph, Karthaus, Meinolf, Kern, Winfried, Krüger, William, Maschmeyer, Georg, Ritter, Jörg, Salwender, Hans J., Sandherr, Michael, Schiel, Xaver, Schüttrumpf, Silke, Sieniawski, Michal, Silling, Gerda, Ullmann, Andrew J., and Wolf, Hans-Heinrich
- Subjects
MYCOSES ,AMPHOTERICIN B ,TUMORS ,NEUTROPENIA - Abstract
Morbidity and mortality in patients with malignancies, especially leukemia and lymphoma, are increased by invasive fungal infections. Since diagnosis of invasive fungal infection is often delayed, antifungal prophylaxis is an attractive approach for patients expecting prolonged neutropenia. Antifungal prophylaxis has obviously attracted much interest resulting in dozens of clinical trials since the late 1970s. The non-absorbable polyenes are probably ineffective in preventing invasive fungal infections, but may reduce superficial mycoses. Intravenous amphotericin B and the newer azoles were used in clinical trials, but their role in antifungal prophylaxis is still not well defined. Allogeneic stem cell transplant recipients are at particularly high risk for invasive fungal infections. Other well described risk factors are neutropenia >10 days, corticosteroid therapy, sustained immunosuppression, graft versus host disease, and concomitant viral infections. The enormous study efforts are contrasted by a scarcity of risk stratified evidence based recommendations for clinical decision making. The objective of this review accumulating information on about 10.000 patients is to assess evidence based criteria primarily regarding the efficacy of antifungal prophylaxis in neutropenic cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
45. Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
- Author
-
Einsele, Hermann, Bertz, Hartmut, Beyer, Jörg, Kiehl, Michael G., Runde, Volker, Kolb, Hans-Jochen, Holler, Ernst, Beck, Robert, Schwerdfeger, Rainer, Schumacher, Ulrike, Hebart, Holger, Martin, Hans, Kienast, Joachim, Ullmann, Andrew J., Maschmeyer, Georg, Krüger, William, Niederwieser, Dietger, Link, Hartmut, Schmidt, Christian A., and Oettle, Helmut
- Subjects
BONE marrow transplantation ,STEM cell transplantation ,EPIDEMIOLOGY ,DISEASES - Abstract
The risk of infection after allogeneic stem cell transplantation is determined by the underlying disease, the intensity of previous treatments and complications that may have occurred during that time, but above all, the risk of infection is determined by the selected transplantation modality (e.g. HLA-match between the stem cell donor and recipient, T cell depletion of the graft, and others). In comparison with patients treated with high-dose chemotherapy and autologous stem cell transplantation, patients undergoing allogeneic stem cell transplantation are at a much higher risk of infection even after hematopoietic reconstitution, due to the delayed recovery of T and B cell functions. The rate at which immune function recovers after hematopoietic reconstitution greatly influences the incidence and type of post-transplant infectious complications. Infection-associated mortality, for example, is significantly higher following engraftment than during the short neutropenic period that immediately follows transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
46. Reply to Denning.
- Author
-
Cornely, Oliver A., Maertens, Johan, Ullmann, Andrew J., Heussel, Claus Peter, and Herbrecht, Raoul
- Subjects
LETTERS to the editor ,ASPERGILLOSIS - Abstract
A response by O.A. Cornely to a letter to the editor about his article about the randomized study of invasive aspergillosis (IA) is presented.
- Published
- 2007
- Full Text
- View/download PDF
47. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
- Author
-
Cornely, Oliver A, Robertson, Michael N, Haider, Shariq, Grigg, Andrew, Geddes, Michelle, Aoun, Mickael, Heinz, Werner J, Raad, Issam, Schanz, Urs, Meyer, Ralf G, Hammond, Sarah P, Mullane, Kathleen M, Ostermann, Helmut, Ullmann, Andrew J, Zimmerli, Stefan, Van Iersel, M L P S, Hepler, Deborah A, Waskin, Hetty, Kartsonis, Nicholas A, and Maertens, Johan
- Subjects
MYCOSES ,PHARMACOKINETICS - Abstract
A correction to the article "Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease" that was published in the October 3, 2017 issue is presented.
- Published
- 2017
- Full Text
- View/download PDF
48. Position paper on current aspects of sponsoring in accredited CME.
- Author
-
Stolz, Daiana, Griebenow, Reinhard, Tichelli, Andre, Ullmann, Andrew J., Costello, Richard W., Michalis, Lampros, Guenova, Margarita, Sutter, Sandy, De Andrade, Fabiola, and Schaefer, Robert
- Subjects
CONTINUING medical education ,EDUCATIONAL accreditation ,EDUCATIONAL programs - Abstract
This position paper is the result of a collaborative approach of several European Specialty Accreditation Boards (ESABs) and, has been stimulated by their current experience in accreditation regarding roles and responsibilities assumed by sponsors of accredited continuing medical education (CME). The suggestions made in this paper aim to preserve the fundamental principle in CME accreditation that the physician in charge of the programme has sole responsibility for the selection of topics, speakers, content and format, as well as mode of presentation, and that sponsors will under no circumstances interfere with this principle. This is considered as a responsibility of an individual physician (or physicians), which cannot be delegated, even in part, to third parties. This responsibility has been extended to include all communication before and after the event. The paper also identifies undecided issues, about which ESABs are committed to elaborate proposals in the future. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
49. Particular Characteristics of Encapsulated Bacteria.
- Author
-
Christopeit, Maximilian, Graubner, Martin, and Ullmann, Andrew J.
- Subjects
BACTERIAL vaccines ,BLOOD diseases ,CANCER patients ,IMMUNIZATION - Abstract
A letter to the editor is presented in response to the article "Vaccination Coverage in Immunosuppressed Patients--Results of a Regional Health Services Research Study," by Niels Teich and colleagues in the 2001 issue.
- Published
- 2011
- Full Text
- View/download PDF
50. Numbers Needed to Treat with Posaconazole Prophylaxis to Prevent Invasive Fungal Infection and Death.
- Author
-
Cornely, Oliver A. and Ullmann, Andrew J.
- Subjects
LETTERS to the editor ,MYCOSES - Abstract
A letter to the editor is presented in response to the article about the numbers needed to treat with Posaconazole to prevent 1 fungal infection or death, which appeared in the previous issue.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.